Menu
← Oncology Approval Tracker
FDA DECISION ·
Breyanzi
lisocabtagene maraleucel · Juno Therapeutics
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adults with large B-cell lymphoma that relapsed or was refractory following at least two systemic treatment lines, including DLBCL, high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma and grade 3B follicular lymphoma.
LAMPGEN ANALYSIS
Why it matters
The original CD19-directed CAR T approval covers a defined heavily treated large B-cell population.
What research teams should watch
Build referral, collection, manufacturing and infusion milestones into screening and follow-up.
PRIMARY RECORDS